Skip to main content

Advertisement

SpringerLink
Log in

Anticoagulation in the management of venous thromboembolism in the cancer patient

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Cancer is associated with a four to sevenfold increased risk of venous thromboembolism (VTE). This risk is influenced by the site and extent of cancer and its treatment. Despite its availability, effective VTE prophylaxis is used in less than 50% of oncology patients. Pharmacologic VTE prophylaxis should be administered to all hospitalized medical and surgical oncology patients for the duration of their hospitalization or up to 10–14 days, whichever is longer. Extended duration (up to 4 weeks post-operation) VTE prophylaxis is recommended for high-risk surgical oncology patients. Routine use of prophylaxis in ambulatory medical oncology patients awaits prospective testing of VTE risk assessment models. Routine prophylactic dose anticoagulation to prevent central venous catheter (CVC) thrombosis is ineffective and not indicated. Low molecular weight heparin is the first line choice for acute and chronic therapy of VTE in cancer patients. Therapy should continue for at least 3 months or the duration of the malignancy, whichever is longer. Anticoagulation is indicated for at least 3 months or the duration of the catheter for CVC thrombosis. Preliminary data indicate that some cancer patients with pulmonary embolism may be managed as outpatients. Prospective validation of these studies and testing of current risk assessment strategies in oncology patients is warranted. Management of recurrent VTE and unsuspected VTE in the cancer patient are also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722. doi:10.1001/jama.293.6.715

    Article  PubMed  CAS  Google Scholar 

  2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815

    Article  PubMed  CAS  Google Scholar 

  3. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119(1):60–68. doi:10.1016/j.amjmed.2005.06.058

    Article  PubMed  Google Scholar 

  4. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464. doi:10.1001/.458

    Article  PubMed  Google Scholar 

  5. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4(3):529–535. doi:10.1111/j.1538-7836.2006.01804.x

    Article  PubMed  CAS  Google Scholar 

  6. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27(29):4839–4847. doi:10.1200/JCO.2009.22.3271

    Article  PubMed  CAS  Google Scholar 

  7. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488. doi:10.1182/blood-2002-01-0108

    Article  PubMed  CAS  Google Scholar 

  8. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr, for the IMPROVE Investigators (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 132(3):936–945. doi:10.1378/chest.06-2993

    Article  PubMed  Google Scholar 

  9. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8(4):381–388

    Article  PubMed  Google Scholar 

  10. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89–95

    Article  PubMed  Google Scholar 

  11. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83(1):14–19

    PubMed  CAS  Google Scholar 

  12. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 341(11):793–800

    Article  PubMed  CAS  Google Scholar 

  13. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110(7):874–879. doi:10.1161/01.CIR.0000138928.83266.24

    Article  PubMed  CAS  Google Scholar 

  14. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, ARTEMIS Investigators (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332(7537):325–329. doi:10.1136/bmj.38733.466748.7C

    Article  PubMed  CAS  Google Scholar 

  15. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group (2003) Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145(4):614–621. doi:10.1067/mhj.2003.189

    Article  PubMed  CAS  Google Scholar 

  16. Streiff MB, National Comprehensive Cancer Center Network (2010) The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 125(Suppl 2):S128–S133. doi:10.1016/S0049-3848(10)70030-X

    Article  PubMed  Google Scholar 

  17. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood. doi:10.1182/blood-2007-10-117051

  18. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505. doi:10.1200/JCO.2007.14.1283

    Article  PubMed  CAS  Google Scholar 

  19. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):381S–453S. doi:10.1378/chest.08-0656

    Article  PubMed  CAS  Google Scholar 

  20. Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822–2829. doi:10.1002/cncr.21496

    Article  PubMed  Google Scholar 

  21. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296(21):2558–2560. doi:10.1001/jama.296.21.2558-c

    Article  PubMed  CAS  Google Scholar 

  22. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423. doi:10.1038/sj.leu.2405062

    Article  PubMed  CAS  Google Scholar 

  23. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, PROTECHT Investigators (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943–949. doi:10.1016/S1470-2045(09)70232-3

    Article  PubMed  CAS  Google Scholar 

  24. Shah MM, Saif MW (2010) Pancreatic cancer and thrombosis. Highlights from the “2010 ASCO annual meeting”. Chicago, IL, USA. June 4-8, 2010. JOP 11(4):331–333

  25. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907. doi:10.1182/blood-2007-10-116327

    Article  PubMed  CAS  Google Scholar 

  26. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382. doi:10.1182/blood-2010-02-270116

    Article  PubMed  CAS  Google Scholar 

  27. Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook DJ, Schunemann HJ (2008) Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 168(12):1261–1269. doi:10.1001/archinte.168.12.1261

    Article  PubMed  CAS  Google Scholar 

  28. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, ENOXACAN II Investigators (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346(13):975–980. doi:10.1056/NEJMoa012385

    Article  PubMed  CAS  Google Scholar 

  29. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olsen B, FAME Investigators (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4(11):2384–2390. doi:10.1111/j.1538-7836.2006.02153.x

    Article  PubMed  CAS  Google Scholar 

  30. Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schunemann HJ (2008) Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thromb Haemost 100(6):1176–1180

    PubMed  CAS  Google Scholar 

  31. Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24(9):1404–1408. doi:10.1200/JCO.2005.03.5600

    Article  PubMed  Google Scholar 

  32. Evans RS, Sharp JH, Linford LH, Lloyd JF, Tripp JS, Jones JP, Woller SC, Stevens SM, Elliott CG, Weaver LK (2010) Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 138(4):803–810. doi:10.1378/chest.10-0154

    Article  PubMed  Google Scholar 

  33. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112(6):423–428

    PubMed  CAS  Google Scholar 

  34. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices–prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75(2):251–253

    PubMed  CAS  Google Scholar 

  35. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Soraru M, Mosca S (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18):4057–4062. doi:10.1200/JCO.2005.06.084

    Article  PubMed  CAS  Google Scholar 

  36. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18):4063–4069. doi:10.1200/JCO.2005.10.192

    Article  PubMed  CAS  Google Scholar 

  37. Carrier M, Tay J, Fergusson D, Wells PS (2007) Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 5(12):2552–2554. doi:10.1111/j.1538-7836.2007.02751.x

    Article  PubMed  CAS  Google Scholar 

  38. Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schunemann HJ (2008) Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer. 112(11):2483–2492. doi:10.1002/cncr.23479

    Article  PubMed  CAS  Google Scholar 

  39. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K, WARP Collaborative Group U. (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373(9663):567–574. doi:10.1016/S0140-6736(09)60205-1

    Article  PubMed  Google Scholar 

  40. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, Lee J, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB, Vedantham S, National Comprehensive Cancer Network (2008) Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 6(8):716–753

    PubMed  CAS  Google Scholar 

  41. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bdair F, Schunemann HJ (2008) Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 113(7):1685–1694. doi:10.1002/cncr.23814

    Article  PubMed  Google Scholar 

  42. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349(18):1695–1702. doi:10.1056/NEJMoa035451

    Article  PubMed  CAS  Google Scholar 

  43. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140(11):867–873

    PubMed  Google Scholar 

  44. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Buller HR (2009) Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 101(4):762–769

    PubMed  Google Scholar 

  45. Shetty R, Seddighzadeh A, Parasuraman S, Vallurupalli NG, Gerhard-Herman M, Goldhaber SZ (2007) Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism. Thromb Haemost 98(6):1384–1386

    PubMed  CAS  Google Scholar 

  46. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729–1735

    Article  PubMed  CAS  Google Scholar 

  47. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J, ONCENOX Investigators (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):389–396. doi:10.1177/1076029606293692

    Article  PubMed  CAS  Google Scholar 

  48. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G, LITE Trial Investigators (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062–1072. doi:10.1016/j.amjmed.2006.02.022

    Article  PubMed  CAS  Google Scholar 

  49. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153. doi:10.1056/NEJMoa025313

    Article  PubMed  CAS  Google Scholar 

  50. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ (2008) Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 27:21. doi:10.1186/1756-9966-27-21

    Article  PubMed  Google Scholar 

  51. Wittkowsky AK (2006) Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 4(9):2090–2091. doi:10.1111/j.1538-7836.2006.02073.x

    Article  PubMed  CAS  Google Scholar 

  52. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Warfarin Optimal Duration Italian Trial Investigators (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345(3):165–169. doi:10.1056/NEJM200107193450302

    Article  PubMed  CAS  Google Scholar 

  53. Grogan KM, Wong C, Nutescu EA, Shord SS (2007) Examining differences in weekly warfarin dose in patients with and without cancer. Ther Drug Monit 29(5):638–643. doi:10.1097/FTD.0b013e318074dc46

    Article  PubMed  CAS  Google Scholar 

  54. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, American College of Chest Physicians (2008) Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):454S–545S. doi:10.1378/chest.08-0658

    Article  PubMed  CAS  Google Scholar 

  55. Louzada ML, Lazo-Langner A, Dao V, Zhang J, Kovacs MJ,Carrier M, Rodger M, Wells P (2010) Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Blood 116(21):475a

    Google Scholar 

  56. Seddighzadeh A, Shetty R, Goldhaber SZ (2007) Venous thromboembolism in patients with active cancer. Thromb Haemost 98(3):656–661

    PubMed  CAS  Google Scholar 

  57. Munoz FJ, Mismetti P, Poggio R, Valle R, Barron M, Guil M, Monreal M, RIETE Investigators (2008) Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE registry. Chest 133(1):143–148. doi:10.1378/chest.07-1432

    Article  PubMed  Google Scholar 

  58. Linenberger ML (2006) Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw 4(9):889–901

    PubMed  Google Scholar 

  59. Ascher E, Salles-Cunha S, Hingorani A (2005) Morbidity and mortality associated with internal jugular vein thromboses. Vasc Endovascular Surg 39(4):335–339

    Article  PubMed  Google Scholar 

  60. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, Andreou R, Mangel JE, Morrow B, Clement AM, Wells PS (2007) A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 5(8):1650–1653. doi:10.1111/j.1538-7836.2007.02613.x

    Article  PubMed  CAS  Google Scholar 

  61. Tran H, Arellano M, Chamsuddin A, Flowers C, Heffner LT, Langston A, Lechowicz MJ, Tindol A, Waller E, Winton EF, Khoury HJ (2010) Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leuk Lymphoma 51(8):1473–1477. doi:10.3109/10428194.2010.481065

    Article  PubMed  Google Scholar 

  62. Monreal M, Falga C, Valdes M, Suarez C, Gabriel F, Tolosa C, Montes J, Riete Investigators (2006) Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 4(9):1950–1956. doi:10.1111/j.1538-7836.2006.02082.x

    Article  PubMed  CAS  Google Scholar 

  63. Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20(12):1907–1912. doi:10.1093/annonc/mdp369

    Article  PubMed  CAS  Google Scholar 

  64. Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353(9162):1386–1389

    Article  PubMed  CAS  Google Scholar 

  65. Kucher N, Rossi E, De Rosa M, Goldhaber SZ (2005) Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. Arch Intern Med 165(15):1777–1781. doi:10.1001/archinte.165.15.1777

    Article  PubMed  Google Scholar 

  66. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ (2004) Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 110(20):3276–3280. doi:10.1161/01.CIR.0000147612.59751.4C

    Article  PubMed  Google Scholar 

  67. Vuilleumier N, Le Gal L, Verschuren F, Perrier A, Bounameaux H, Turck N, Sanchez JC, Mensi N, Perneger T, Hochstrasser D, Righini M (2009) Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 7(3):391–398. doi:10.1111/j.1538-7836.2008.03260.x

    Article  PubMed  CAS  Google Scholar 

  68. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF (2000) Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 84(4):548–552

    PubMed  CAS  Google Scholar 

  69. Nendaz MR, Bandelier P, Aujesky D, Cornuz J, Roy PM, Bounameaux H, Perrier A (2004) Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 91(6):1232–1236. doi:10.1267/THRO04061232

    PubMed  CAS  Google Scholar 

  70. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ (2005) Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172(8):1041–1046. doi:10.1164/rccm.200506-862OC

    Article  PubMed  Google Scholar 

  71. Aujesky D, Roy PM, Le Manach CP, Verschuren F, Meyer G, Obrosky DS, Stone RA, Cornuz J, Fine MJ (2006) Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 27(4):476–481. doi:10.1093/eurheartj/ehi588

    Article  PubMed  Google Scholar 

  72. Donze J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, Cornuz J, Meyer G, Perrier A, Righini M, Aujesky D (2008) Prospective validation of the pulmonary embolism severity index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 100(5):943–948

    PubMed  CAS  Google Scholar 

  73. Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD, RIETE Investigators. (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170(15):1383–1389. doi:10.1001/archinternmed.2010.199

    Article  PubMed  Google Scholar 

  74. Kovacs MJ, Hawel JD, Rekman JF, Lazo-Langner A (2010) Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost. doi:10.1111/j.1538-7836.2010.03981.x

  75. Erkens PM, Gandara E, Wells P, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, Carrier M (2010) Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost. doi:10.1111/j.1538-7836.2010.04041.x

  76. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349(12):1133–1138. doi:10.1056/NEJMoa035241

    Article  PubMed  CAS  Google Scholar 

  77. Luk C, Wells PS, Anderson D, Kovacs MJ (2001) Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111(4):270–273

    Article  PubMed  CAS  Google Scholar 

  78. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY (2009) Dose escalation of low molecular weight heparin to manage recurrent venous thromboemblic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. doi:10.1111/j.1538-7836.2009.03326.x

  79. Varki A (2007) Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 110(6):1723–1729. doi:10.1182/blood-2006-10-053736

    Article  PubMed  CAS  Google Scholar 

  80. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 189(1):162–170. doi:10.2214/AJR.07.2067

    Article  PubMed  Google Scholar 

  81. O’Connell CL, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman HA (2006) Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 24(30):4928–4932. doi:10.1200/JCO.2006.06.5870

    Article  PubMed  Google Scholar 

  82. Lee EY, Kritsaneepaiboon S, Arellano CM, Grace RF, Zurakowski D, Boiselle PM (2010) Unsuspected pulmonary emboli in pediatric oncology patients: detection with MDCT. AJR Am J Roentgenol 194(5):1216–1222. doi:10.2214/AJR.09.3463

    Article  PubMed  Google Scholar 

  83. Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Buller HR, Feragalli B, Porreca E (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104(5):1049–1054. doi:10.1160/TH10-05-0277

    PubMed  CAS  Google Scholar 

  84. O’Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA (2011) Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging MDCT scanning. J Thromb Haemost 9(2):305–311. doi:10.1111/j.1538-7836.2010.04114.x

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, 1830 East Monument Street, Suite 7300, Baltimore, MD, 21205, USA

    Michael B. Streiff

Authors
  1. Michael B. Streiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Streiff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Streiff, M.B. Anticoagulation in the management of venous thromboembolism in the cancer patient. J Thromb Thrombolysis 31, 282–294 (2011). https://doi.org/10.1007/s11239-011-0562-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-011-0562-0

Keywords

Search

Navigation